FinancialContent is the trusted provider of stock market information to the media industry.
February 17, 2012 at 11:10 AM EST
Gilead Reports Disappointing Results
Gilead Sciences Inc. (Nasdaq: GILD) reported disappointing results from a trial of its hepatitis C treatment GS-7977. Shares of the biopharmaceutical plummeted $8.19 to $46.62.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here